Shandong Jincheng Pharmaceutical (SHE:300233) unit Beijing Jincheng Tail Pharmaceutical obtained Good Manufacturing Practice compliance certification for its erythromycin lactobionate active pharmaceutical ingredient.
The approval was granted by Beijing drug regulators following an on-site inspection in late October 2025, according to a filing with the Shenzhen bourse.
The certification clears the way for domestic production and sales of the macrolide antibiotic.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.